...
首页> 外文期刊>Journal of chemical information and modeling >Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A(2A) Adenosine Receptor
【24h】

Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A(2A) Adenosine Receptor

机译:分子对接筛选使用激动剂绑定的GPCR结构:探索A(2A)腺苷受体。

获取原文
获取原文并翻译 | 示例
           

摘要

Crystal structures of G protein-coupled receptors (GPCRs) have recently revealed the molecular basis of ligand binding and activation, which has provided exciting opportunities for structure-based drug design. The A(2A) adenosine receptor (A(2A)AR) is a promising therapeutic target for cardiovascular diseases, but progress in this area is limited by the lack of novel agonist scaffolds. We carried out docking screens of 6.7 million commercially available molecules against active-like conformations of the A(2A)AR to investigate whether these structures could guide the discovery of agonists. Nine out of the 20 predicted agonists were confirmed to be A(2A)AR ligands, but none of these activated the ARs. The difficulties in discovering AR agonists using structure-based methods originated from limited atomic-level understanding of the activation mechanism and a chemical bias toward antagonists in the screened library. In particular, the composition of the screened library was found to strongly reduce the likelihood of identifying AR agonists, which reflected the high ligand complexity required for receptor activation. Extension of this analysis to other pharmaceutically relevant GPCRs suggested that library screening may not be suitable for targets requiring a complex receptor-ligand interaction network. Our results provide specific directions for the future development of novel A(2A)AR agonists and general strategies for structure-based drug discovery.
机译:G蛋白偶联受体(GPCR)的晶体结构最近揭示了配体结合和激活的分子基础,这为基于结构的药物设计提供了令人兴奋的机会。 A(2A)腺苷受体(A(2A)AR)是心血管疾病的有希望的治疗靶标,但是由于缺乏新型激动剂支架,该领域的进展受到了限制。我们对A(2A)AR的类似活性构象的670万种可商购分子进行了对接筛选,以研究这些结构是否可以指导激动剂的发现。在20种预测激动剂中,有9种被确认为A(2A)AR配体,但这些都没有激活AR。使用基于结构的方法发现AR激动剂的困难源于对激活机制的有限原子级理解以及对筛选文库中拮抗剂的化学偏倚。特别地,发现筛选的文库的组成大大降低了鉴定AR激动剂的可能性,这反映了受体激活所需的高配体复杂性。将该分析扩展到其他药学相关的GPCR,表明文库筛选可能不适合需要复杂受体-配体相互作用网络的靶标。我们的结果为新型A(2A)AR激动剂的未来发展和基于结构的药物发现的一般策略提供了具体的方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号